Novo files for hemophilia drug OK; Fate Therapeutics names new CEO; Shenzhen Hepalink invests in ProMetic;

 @FierceBiotech: New special report on 10 promising therapeutic vaccines in 2012. Feature | Follow @FierceBiotech

 @JohnCFierce: Genzyme, likely to get some tough safety questions on Kynamro at this week's FDA panel. More | Follow @JohnCFierce

 @RyanMFierce: Piramal is poised to be a big consolidator in pharma services/manufacturing, but apparently only at the right price. More | Follow @RyanMFierce

> Novo Nordisk ($NVO) has filed for regulatory approval of its hemophilia drug Turoctocog Alfa in the U.S. and Europe. Report

> Fate Therapeutics named Christian Weyer as its new president and chief executive officer. Release

> China's Shenzhen Hepalink Pharmaceutical is making a $10 million investment in Canada's ProMetic Life Sciences while striking two R&D pacts worth up to $21 million. Story

Pharma News

@FiercePharma: Other compounded drugs may be tied into meningitis outbreak, FDA says. Another NECC steroid + NECC heart drug. More | Follow @FiercePharma

> J&J credits Remicade, Zytiga for 7% hike in Q3 drug sales. Story

> Roche sales hike sums up pharma hopes for cancer, emerging markets. Article

> India kicks branded generics to the curb. Report

Medical Device News

 @FierceMedDev: JNJ pulled in $7.1 billion from medical devices and diagnostics in Q3, a 12.5% jump. More | Follow @FierceMedDev

 @MarkHFierce: Patients in India thrived with used ICD implants. Can this be done on a broader scale? More | Follow @MarkHFierce

 @DamianFierce: Medtronic is buying a $66.2M stake in China's LifeTech Scientific, makers of cardiovascular devices. More | Follow @DamianFierce

> Amid Dx sales growth, Roche Diagnostics considers another buy. News

> Lanx draws $8.7M for spinal fusion device development. Item

Biotech Research News

> NIH funds Advanced Cancer Therapeutics' preclinical brain cancer drug work. Report

> Scientists flee $3B Texas cancer research fund. Item

> Alnylam, Tel Aviv U develop RNAi drugs to fight rare blood cancer. Article

> Alzheimer's drug builds new brain cell connections in rats. News

> Scientists build neural-like stem cells from mouse muscle tissue. Story

Pharma Manufacturing News

> GSK cancels plans to close Stiefel plant in Ireland. Story

> Cinven continues generics deal spree with Amdipharm buy. Article

> Teva Pharma opens $110M plant in Hungary. News

> Analysis: Compounding groups fought FDA oversight before NECC disaster. Report

And Finally... Postdoctoral Research Fellow Devin Koestler and colleagues are investigating the potential use of white blood cell variation as a diagnostic and research tool for cancer. Release


Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.